Posted on Oct. 25, 2021, 9:00 p.m.
A second reminder for almost everyone. The European Medicines Agency on Monday approved the administration of a third dose of the Moderna laboratory’s anti-Covid vaccine to people aged 18 and over. This news comes as winter approaches, as Europe begins to worry about a new pandemic wave faster than expected.
Spikevax, the name of the vaccine from the American biotech led by French Stéphane Bancel, is the second booster to receive the green light after the vaccine from Pfizer / Biontech earlier this month. Time is running out: it is about allowing people who received vaccination coverage at the end of last winter to upgrade their immune response to the coronavirus.
Mix the vaccines
“Data showed that a third dose of Spikevax given six to eight months after the second dose resulted in increased antibody levels in adults with declining antibody levels,” said the European Medicines Agency to justify its decision.
“The risk of inflammatory heart problems and other very rare side effects after a booster is carefully monitored,” says the EMA, adding that the booster dose consists of half of the dose used during first two injections.
Allowing multiple vaccines for a third dose would give Europe the ability to conduct a vaccine combination strategy, which could help optimize vaccine coverage. A patient who received his first two doses with Moderna’s vaccine could thus receive a Pfizer booster dose, for example.
As a reminder, the Pfizer-BioNTech, Moderna, Johnson & Johnson and AstraZeneca vaccines are the only vaccines currently authorized in the European Union for the first two doses.